Tallac Therapeutics, Inc., a Burlingame, Calif.-based biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, raised $62m in Series A financing.
Backers included venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China, and MRL Ventures Fund.
The company plans to use the funding to advance the discovery and development of immunotherapy candidates for multiple solid tumor maligniancies. Its pipeline of next generation immunotherapies are derived from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform.
Founded in 2018 by Dr. Hong I. Wan, president and CEO, Corey Goodman, board chair and Managing Partner at venBio, Dr. Jaume Pons (currently CEO of ALX Oncology) and Dr. Curt Bradshaw (most recently CSO at Arrowhead Pharmaceuticals), Tallac Therapeutics is a biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Its pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.